Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
This article was originally published in The Pink Sheet Daily
Executive Summary
Launching a competing epinephrine product has proved challenging, which is good news for Mylan. Teva disclosed the receipt of a complete response letter to its ANDA, just months after Sanofi voluntarily recalled Auvi-Q due to inaccurate dose delivery.
You may also be interested in...
Teva Launches Generic EpiPen At Same Price As Mylan's Generic
Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.
Teva Launches Generic EpiPen At Same Price As Mylan's Generic
Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
The latest drug development news and highlights from our US FDA Performance Tracker.